117 related articles for article (PubMed ID: 7624917)
1. Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): implication for area under the concentration-time curve monitoring.
Nakashima H; Lieberman R; Karato A; Arioka H; Ohmatsu H; Nomura N; Shiraishi J; Tamura T; Eguchi K; Shinkai T
Ther Drug Monit; 1995 Jun; 17(3):221-9. PubMed ID: 7624917
[TBL] [Abstract][Full Text] [Related]
2. Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
Chabot GG
Cancer Chemother Pharmacol; 1995; 36(6):463-72. PubMed ID: 7554037
[TBL] [Abstract][Full Text] [Related]
3. CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer.
Yamamoto N; Tamura T; Karato A; Uenaka K; Eguchi K; Shinkai T; Ohe Y; Oshita F; Arioka H; Nakashima H
Jpn J Cancer Res; 1994 Sep; 85(9):972-7. PubMed ID: 7961128
[TBL] [Abstract][Full Text] [Related]
4. Limited sampling models for CPT-11, SN-38, and SN-38 glucuronide.
Sloan JA; Atherton P; Reid J; Pitot HC; Erlichman C; Schaaf L
Cancer Chemother Pharmacol; 2001 Sep; 48(3):241-9. PubMed ID: 11592347
[TBL] [Abstract][Full Text] [Related]
5. Limited sampling model for the area under the concentration versus time curve of irinotecan and its application to a multicentric phase II trial.
Yamamoto N; Tamura T; Nishiwaki Y; Kurita Y; Kawakami Y; Abe S; Nakabayashi T; Suzuki S; Matsuda T; Hayashi I; Takahashi T; Saijo N
Clin Cancer Res; 1997 Jul; 3(7):1087-92. PubMed ID: 9815787
[TBL] [Abstract][Full Text] [Related]
6. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
Mick R; Gupta E; Vokes EE; Ratain MJ
J Clin Oncol; 1996 Jul; 14(7):2012-9. PubMed ID: 8683231
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic investigation of irinotecan hydrochloride in pediatric patients with recurrent or progressive solid tumors.
Kimura T; Kashiwase S; Makimoto A; Kumagai M; Taga T; Ishida Y; Ida K; Nagatoshi Y; Mugishima H; Kaneko M; Barrett JS
Int J Clin Pharmacol Ther; 2010 May; 48(5):327-34. PubMed ID: 20420789
[TBL] [Abstract][Full Text] [Related]
8. A limited sampling model for estimating pharmacokinetics of CPT-11 and its metabolite SN-38.
Sasaki Y; Mizuno S; Fujii H; Ohtsu T; Wakita H; Igarashi T; Itoh K; Sekine I; Miyata Y; Saijo N
Jpn J Cancer Res; 1995 Jan; 86(1):117-23. PubMed ID: 7737903
[TBL] [Abstract][Full Text] [Related]
9. Sparse-data set analysis for irinotecan and SN-38 pharmacokinetics in cancer patients co-treated with cisplatin.
Mathijssen RH; van Alphen RJ; de Jonge MJ; Verweij J; de Bruijn P; Loos WJ; Nooter K; Vernillet L; Stoter G; Sparreboom A
Anticancer Drugs; 1999 Jan; 10(1):9-16. PubMed ID: 10194542
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors.
Drengler RL; Kuhn JG; Schaaf LJ; Rodriguez GI; Villalona-Calero MA; Hammond LA; Stephenson JA; Hodges S; Kraynak MA; Staton BA; Elfring GL; Locker PK; Miller LL; Von Hoff DD; Rothenberg ML
J Clin Oncol; 1999 Feb; 17(2):685-96. PubMed ID: 10080615
[TBL] [Abstract][Full Text] [Related]
11. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.
Peng B; Boddy AV; Cole M; Pearson AD; Chatelut E; Rubie H; Newell DR
Eur J Cancer; 1995 Oct; 31A(11):1804-10. PubMed ID: 8541105
[TBL] [Abstract][Full Text] [Related]
12. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.
Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; van Hoek B
Aliment Pharmacol Ther; 2005 Mar; 21(5):549-57. PubMed ID: 15740538
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11.
Miya T; Goya T; Fujii H; Ohtsu T; Itoh K; Igarashi T; Minami H; Sasaki Y
Invest New Drugs; 2001; 19(1):61-7. PubMed ID: 11291833
[TBL] [Abstract][Full Text] [Related]
14. Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model.
Asai G; Ando Y; Saka H; Ando M; Sugiura S; Sakai S; Hasegawa Y; Shimokata K
Eur J Clin Pharmacol; 1998; 54(9-10):725-7. PubMed ID: 9923575
[TBL] [Abstract][Full Text] [Related]
15. A limited sampling strategy to estimate the pharmacokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen.
Poujol S; Pinguet F; Ychou M; Abderrahim AG; Duffour J; Bressolle FM
Oncol Rep; 2007 Dec; 18(6):1613-321. PubMed ID: 17982652
[TBL] [Abstract][Full Text] [Related]
16. Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.
Baille P; Bruno R; Schellens JH; Webster LK; Millward M; Verweij J; Montay G
Clin Cancer Res; 1997 Sep; 3(9):1535-8. PubMed ID: 9815840
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11.
Sasaki Y; Yoshida Y; Sudoh K; Hakusui H; Fujii H; Ohtsu T; Wakita H; Igarashi T; Itoh K
Jpn J Cancer Res; 1995 Jan; 86(1):111-6. PubMed ID: 7737902
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients.
de Forni M; Bugat R; Chabot GG; Culine S; Extra JM; Gouyette A; Madelaine I; Marty ME; Mathieu-Boué A
Cancer Res; 1994 Aug; 54(16):4347-54. PubMed ID: 8044782
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
